Acute Lymphoblastic Leukemia

The TARGET Acute Lymphoblastic Leukemia projects elucidate comprehensive molecular characterization to determine the genetic changes that drive the initiation and progression of hard-to-treat childhood cancers. The ALL project team has generated data in two distinct primary discovery phases with separate patient cohorts and analyses. The ALL Pilot Phase (Phase I) began in 2007 to study the benefits of comprehensively profiling the genome of pediatric childhood cancers. The TARGET initiative evolved from the success of that pilot effort, to include an additional genomics projects in ALL (Expansion Phase or Phase II; Acute Leukemias of Ambiguous Lineage or Phase III), along with other pediatric blood and solid tumor malignancies. 

Acute lymphoblastic leukemia (ALL) is a cancer of white blood cells, the cells in the body that normally fight infection. It is the most common cancer in children. Over the last several decades, advances in the treatment and supportive care of pediatric ALL have dramatically increased its 5-year survival rate to almost 90%. Despite these improvements, a considerable number of children with ALL continue to relapse following standardized treatment. Accurately diagnosing those patients who are high-risk (HR) for relapse and treating them with targeted therapies may greatly enhance their outcomes.

The ALL Pilot Phase (Phase I) project has been completed, and ALL P1 datasets are now available without restrictions on their use in publications or presentations. The ALL project team is currently working on publications to include an integrated manuscript of the disease landscape for the ALL Expansion Phase (Phase II). Please refer to the TARGET Publication Guidelines page to see which ALL P2 datasets are available without restrictions on their use in publications or presentations.

Last updated: January 23, 2019